The Board of Directors of Bioalpha Holdings Berhad (“Bioalpha” or “the Company”) wishes to announce that Bioalpha International Sdn. Bhd. (“BISB”), a wholly-owned subsidiary of Bioalpha has on 25 January 2021 entered into a Procurement and Distribution Agreement (“Agreement”) with Shanghai Bukun Trading Co., Ltd (“SBTC”), a wholly-owned subsidiary of Sinopharm (Hainan) Health Industry Co., Ltd (“Sinopharm Hainan”) for the procurement and distribution of vaccines in Malaysia, including but not limited to the Covid-19 vaccine developed by Sinovac Biotech Co., Ltd. (“Sinovac Biotech”), subject to relevant authorities’ approvals which include the National Pharmaceutical Regulatory Agency (“NPRA”). This arrangement has also been endorsed by Sinovac Biotech with regards to the Covid-19 vaccine.

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123824

https://www.theedgemarkets.com/article/bioalpha-join-vaccine-distribution-bandwagon

https://www.theedgemarkets.com/article/bioalpha-join-vaccine-distribution-bandwagon

https://www.theedgemarkets.com/article/bioalpha-join-vaccine-distribution-bandwagon

https://www.bursamalaysia.com/market_information/announcements/company_announcement/announcement_details?ann_id=3123824

That one is Sinovac not Sinopharm. Read carefully.

scenery, help us chase him away from this forum pls

UlarSawa busuk hati la. One day god will punish you for your sins.

Looks like price cannot sustain going down

Of course bamboo is core business and will contribute the most but now is vaccine theme

Sinopharm vaccine may be less vulnerable to Covid-19 variants, say immunologists

Inactivated shots made using a 'dead' version of the virus could give people better protection against mutated variants seen in the UK, South Africa and elsewhere

Inactivated vaccines may be more effective against fighting new mutated strains of the coronavirus, according to a top immunologist.

Such vaccines, including the UAE-approved Sinopharm, use a “dead” version of the whole virus, offering protection against multiple areas.

That means they may hold up better against variants.

Luke O’Neill, professor of biochemistry in the School of Biochemistry and Immunology at Trinity College Dublin, said because inactivated vaccines are based on the whole virus, the immune system will have “lots of weapons against lots of parts of the vaccine”.

“The whole virus vaccines are very likely to work against any variant.”

https://www.thenationalnews.com/uae/health/sinopharm-vaccine-may-be-less-vulnerable-to-covid-19-variants-say-immunologists-1.1152392

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

WHO to consider Sinopharm, Sinovac Covid-19 vaccines next week

GENEVA (Jan 22): The World Health Organization will begin considering China's two COVID-19 vaccines for emergency approval next week, WHO Assistant Director-General Mariangela Simao said on Friday.

China is promoting two vaccines, made by Sinopharm and Sinovac, and has signed deals to export millions of doses of both of them. Simao said the WHO was also looking into providing emergency approval for AstraZeneca's vaccine from manufacturing sites in South Korea and India.

https://www.theedgemarkets.com/article/who-consider-sinopharm-sinovac-covid19-vaccines-next-week

@dragon_loong Distribution here refers to distribution of vaccine for clinical trial participants, not distribution of vaccine for general public use. Inix will sponsor the vaccines for use in the clinical trial as part of their CORPORATE SOCIAL RESPONSIBILITY (CSR) INITIATIVE.


Read until the end, especially the last paragrah of the 1st announcement. The hint is there.

“ As and when iNix has received the approval from MoH, iNix would be able to import the vaccine and supply the same to MoH to conduct 3rd Phase Clinical Trial in which it would be fully sponsored by iNix as INIX’s CSR initiative. This first clinical trial in Malaysia is expected to involve approximately 3,000 volunteers.”


The “approval” here refers to the approval to import the vaccine for purpose of clinical trial only and not approval for general public use in Malaysia. Otherwise why do you still need to conduct clinical trials when the approval of the vaccine by MOH is for general public use? Inix is playing around with words here to confuse and mislead the shareholders.

Besides, there is no MOU or official distributor agreement between Sinovac, Cansino and Sinopharm with Inix. Otherwise, it would have been announced in Bursa Malaysia.

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=110697&name=EA_GA_ATTACHMENTS

lololol

https://www.theedgemarkets.com/article/khairy-explains-malaysias-vaccine-procurement-process-delivery-schedule

Egypt begins mass COVID-19 vaccination campaign

Egyptian President Abdel Fattah El-Sisi announced the start of the campaign, and said that medical staff will be first in line to receive the jab.

Egypt received the first shipment of vaccines developed by Sinopharm last December.

https://www.arabnews.com/node/1797641/middle-east

Pemerintah UEA Jamin Vaksin Sinopharm Halal
https://www.liputan6.com/bisnis/read/4433356/pemerintah-uea-jamin-vaksin-sinopharm-halal

UlarSawa Be patient. Vaccine dream takes time.

Ularsawa 20% of the population still not covered. Furthermore, not all vaccine will arrive at the same time, some may arrive earlier but the rest will only arrive in 3rd or 4th quarter 2021. So whichever vaccine is arrives earlier will be have the advantage. Furthermore, Sinopharm has clinical data to show that it can be used in children aged 3-17 years old whereas other vaccines do not have such clinical data and can only be used in adults. So Sinopharm can fill in the gap for vaccination of children.

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti
https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

UlarSawa i didnt bring it up. You were the on whobrought up the topic of Inix so i was just explaining it to you.

Khairy did not choose Sinopharm as Sinopharm is meant for private sector use.

https://www.theedgemarkets.com/article/no-objection-kanger-purchase-covid19-vaccine

UlarSawa Up to you want you want to dream. As for me vaccine dream is still alive, only a matter of time.

Inix wants to sponsor the vaccine for clinical trials, hence they need to apply to NPRA for the clinical trial import license. Cannot simply import for clinical trials without prior approval from NPRA.

UlarSawa The “approval” refers to approval to import the vaccine for clinical trial ONLY and not approval to market in Malaysia for general public use. Read the first announcemnet carefully.

UlarSawa must have faith in Kanger. and be positive The vaccine dream is still alive. Bamboo also alive. Glove dream maybe later on. Dont be so negative. Negativity will affect your health.

Inix no MOU or agreement means TIPU one.

The application is not application for registration for marketing to general public but application to import the vaccine for clinical trials only as they wish to sponsor the vaccine for clinical trial as part of their Corporate Social Responsibility (CSR) initiative. Read carefully.

The application is referring to application to import the vaccine for clinical trial ONLY.

The role of Inix is only to distribute the vaccines for clinical trial. It is part of their CSR INITIATIVE.

Read the last part. The hint is there “ As and when iNix has received the approval from MoH, iNix would be able to import the vaccine and supply the same to MoH to conduct 3rd Phase Clinical Trial in which it would be fully sponsored by iNix as INIX’s CSR initiative. This first clinical trial in Malaysia is expected to involve approximately 3,000 volunteers.” The “approval” refers to approval to import the vaccine for clinical trial and not approval to market in Malaysia. Otherwise why do you still need to conduct clinical trials when the vaccine has already been approved by MOH? Conflicting isn’t it ?

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=110697&name=EA_GA_ATTACHMENTS

Inix doesnt have any MOU or official distribution agreement with Sinopharm, sinovac or cansino

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Eurocham: No mention of lockdown after Feb 4 in meeting with Miti

https://www.thestar.com.my/news/nation/2021/01/24/eurocham-no-mention-of-lockdown-after-feb-4-in-meeting-with-miti#.YA1_G6wITnI.whatsapp

Cambodia accepts 1m doses of China's Sinopharm vaccine
https://asia.nikkei.com/Spotlight/Coronavirus/Cambodia-accepts-1m-doses-of-China-s-Sinopharm-vaccine

Ularsawa The role of Inix is only to distribute the vaccines for clinical trial. It is part of their CSR initiative.

Read the last part. The hint is there “ As and when iNix has received the approval from MoH, iNix would be able to import the vaccine and supply the same to MoH to conduct 3rd Phase Clinical Trial in which it would be fully sponsored by iNix as INIX’s CSR initiative. This first clinical trial in Malaysia is expected to involve approximately 3,000 volunteers.” The “approval” refers to approval to import the vaccine for clinical trial and not approval to market in Malaysia. Otherwise why do you still need to conduct clinical trials when the vaccine has already been approved by MOH? Conflicting isn’t it ?

https://disclosure.bursamalaysia.com/FileAccess/apbursaweb/download?id=110697&name=EA_GA_ATTACHMENTS

Hungary plans to 'quickly' approve China's Sinopharm COVID-19 vaccine
https://newseu.cgtn.com/news/2021-01-16/Hungary-plans-to-quickly-approve-China-s-Sinopharm-COVID-19-vaccine-X52oJCsAMM/index.html

Serbia Becomes First European Nation To Use China's Sinopharm Vaccine
https://www.rferl.org/a/serbia-covid-vaccine-china-sinopharm/31053091.html

WHO to consider Sinopharm, Sinovac Covid-19 vaccines next week

GENEVA (Jan 22): The World Health Organization will begin considering China's two COVID-19 vaccines for emergency approval next week, WHO Assistant Director-General Mariangela Simao said on Friday.

China is promoting two vaccines, made by Sinopharm and Sinovac, and has signed deals to export millions of doses of both of them. Simao said the WHO was also looking into providing emergency approval for AstraZeneca's vaccine from manufacturing sites in South Korea and India.

https://www.theedgemarkets.com/article/who-consider-sinopharm-sinovac-covid19-vaccines-next-week